Changes in Hong Kong stocks | Corning Jerry Pharmaceutical-B (09966) rose by nearly 5% JSKN003 has been granted breakthrough therapy certification by the FDA

The Zhitong Finance App learned that Corning Jerry Pharmaceutical-B (09966) rose by nearly 5%. As of press release, it had risen 4.87% to HK$11.19, with a turnover of HK$8.5316 million.

According to the news, on December 18, Corning Jerry Pharmaceutical-B announced that JSKN003 has been granted breakthrough therapy certification (“BTD”) by the US Food and Drug Administration (“FDA”) to treat advanced or metastatic human epidermal growth factor receptor 2 (“HER2”) expressed (IHC 1+, 2+, and 3+) platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (collectively known as “PROC”)) Adult patients.

Previously, JSKN003 was approved by the FDA to conduct a phase II clinical trial to treat PROC with unlimited HER2 expression levels, and was granted BTD by the National Drug Administration (“China Drug Administration”) Drug Evaluation Center for PROC and colorectal cancer (CRC), fast track qualification by the FDA for PROC and gastroesophageal junction cancer (GC/GEJ) by the FDA. The award of BTD has further demonstrated the confidence of international regulators in the clinical potential of JSKN003 and its importance as a candidate for a novel treatment.